Skip to main content
. 2010 Aug 24;103(6):827–836. doi: 10.1038/sj.bjc.6605832

Figure 4.

Figure 4

Immunofluorescence analysis of F16–IL2 fusion protein localisation in subcutaneous (A) and intracranial (B) glioblastoma xenografts, 24 h after the third injection of therapeutic agents (serial tissue sections). Scale bars indicate 100 μm.